Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight

The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, including Regorafenib (Bayer), AV-GBM-1 (Aivita Biomedical), Enzastaurin (DB-102) (Denovo Biopharma), Paxalisib (GDC-0084) (Kazia Therapeutics), and others, aimed at improving patient outcomes.New York, USA, Aug. 10, 2026 (GLOBE NEWSWIR